Systemic disease

RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy

Retrieved on: 
Thursday, February 22, 2024

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy.
  • The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes.
  • Furthermore, it allows for the detection and analysis of various conditions of the eye, such as, hydration, innervations, inflammation, circulation, nerve conduction, etc.
  • Some of the best-studied ocular conformational diseases include cataracts in the lens and retinitis pigmentosa in the retina.

Proclaim™ Custom-Jet Oral Health System Eliminates Bacteria in the Mouth Linked to Heart Disease, Alzheimer's, Diabetes, Certain Cancers and More - in Just 7 Seconds a Day

Retrieved on: 
Tuesday, January 9, 2024

MOUNTAIN VIEW, Calif., Jan. 9, 2024 /PRNewswire/ -- Customized preventative health company Proclaim™ today announces its world-changing mission to save millions of lives by eradicating P. Gingivalis – the silent, dangerous bacteria lurking in nearly everyone's mouths. In just 7 seconds at the push of a button, the clinically proven Custom-Jet Oral Health System comfortably blasts away this potentially life-threatening bacteria from your mouth, along with plaque, food and other debris.

Key Points: 
  • In just 7 seconds at the push of a button, the clinically proven Custom-Jet Oral Health System comfortably blasts away this potentially life-threatening bacteria from your mouth, along with plaque, food and other debris.
  • "If you could improve your oral health in just seconds a day, why wouldn't you?
  • The Custom-Jet Oral Health System is clinically proven to reduce the signs of gum disease.
  • Proclaim Custom-Jet Oral Health System is now available at ProclaimHealth.com for $899 – and for a limited time, consumers can receive $100 off.

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

Retrieved on: 
Monday, December 4, 2023

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D.

Key Points: 
  • PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D.
  • RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
  • Dr. Boneva said, “I am very excited about joining the RetinalGeniX Board of Directors.
  • Jerry Katzman MD, Chairman, President, and CEO of RetinalGeniX Technologies Inc., said, “We are delighted to welcome Dessy aboard.

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.

Retrieved on: 
Monday, December 4, 2023

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).

Key Points: 
  • The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selective HDAC6 inhibitor, for amyotrophic lateral sclerosis (ALS).
  • Dr. Jordi Xaus, Oryzon’s CSO, said: “It is an honor to have the support of the ALS Association.
  • Established in 1985, the ALS Association is the largest philanthropic funder of ALS research in the world.
  • The Association is working to make ALS a livable disease while urgently searching for new treatments and a cure.

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

Retrieved on: 
Wednesday, November 1, 2023

THOUSAND OAKS, Calif., Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

Key Points: 
  • Abstract #2161, Poster Session C: RA – Treatments Poster III, Tuesday, Nov. 14 from 9-11am PST
    Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Abstract #0441, Poster Session A: RA – Treatments Poster I, Sunday, Nov. 12 from 9-11am PST
    Treatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
    Abstract #0236, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database
    Abstract #0237, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0239, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Abstract #0242, Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I, Sunday, Nov. 12 from 9-11am PST
    Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
    Abstract #1102, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1103, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1107, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1108, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Real-world Trends in the Use of Immunomodulation as Co-Therapy to Pegloticase: Claims-Based Findings Since 2016
    Abstract #1123, Poster Session B: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II, Monday, Nov. 13 from 9-11am PST
    Abstract #1145, Poster Session B: Miscellaneous Rheumatic & Inflammatory Diseases Poster II, Monday, Nov. 13 from 9-11am PST
    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies
    Abstract #1691, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 5-5:10pm PST
    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
    Abstract #1690, Oral Abstract Session: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA, Monday Nov. 13 from 4:45-4:55pm PST
    Abstract #0966, Poster Session B: Epidemiology & Public Health Poster II, Monday Nov. 13 from 9-11am PST
    Abstract #1041, Poster Session B: Imaging of Rheumatic Diseases Poster I, Monday Nov. 13 from 9-11am PST
    Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients With Early Oligoarticular Psoriatic Arthritis: 16-Week Results From FOREMOST
    Abstract #1413, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Abstract #1414, Poster Session B: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA, Monday Nov. 13 from 9-11am PST
    Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
    Abstract #2528, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:15-4:25pm PST
    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2529, Oral Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science, Tuesday, Nov. 14 from 4:30-4:40pm PST
    Comparative Effectiveness of Denosumab versus Alendronate among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
    Abstract #2008, Poster Session C: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0683, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0684, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0685, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #0686, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST
    Abstract #2379, Poster Session C: Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes, Tuesday, Nov. 14 from 9-11am PST
    Abstract #0171, Poster Session A: Health Services Research Poster I, Sunday, Nov. 12 from 9-11am PST
    Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren's Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
    Abstract #1636, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Abstract #1638, Oral Abstract Session: Sjögren's Syndrome – Basic & Clinical Science, Monday, Nov. 13 from 2-3:30pm PST
    Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren's Disease: Results from a Multinational, Real-World Survey
    Abstract #1369, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjögren's Syndrome
    Abstract #1379, Poster Session B: Sjögren's Syndrome – Basic & Clinical Science Poster I, Monday, Nov. 13 from 9-11am PST
    Disease Burden of Patients with Primary Sjögren's Disease: Results from a Multinational Real-World Survey
    Abstract #2179, Poster Session C: Sjögren's Syndrome – Basic & Clinical Science Poster II, Tuesday, Nov. 14 from 9-11am PST
    Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
    Abstract #0688, Poster Session A: Vasculitis – ANCA-Associated Poster I: Treatment Outcomes, Sunday, Nov. 12 from 9-11am PST

Curio Wellness Appoints Dr. David "Dedi" Meiri to its Scientific Advisory Board

Retrieved on: 
Wednesday, September 27, 2023

TIMONIUM, Md., Sept. 27, 2023 /PRNewswire/ -- Curio Wellness,  a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced that it has appointed Dr. Dedi Meiri to its Scientific Advisory Board (SAB).

Key Points: 
  • TIMONIUM, Md., Sept. 27, 2023 /PRNewswire/ -- Curio Wellness , a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products, today announced that it has appointed Dr. Dedi Meiri to its Scientific Advisory Board (SAB).
  • Dr. Meiri joins Curio's SAB with extensive education and research in the biochemistry and cannabinoid field, holding an M.Sc.
  • As part of the SAB at Curio, Dr. Meiri will use his expertise to help guide the company's innovations in scientifically-developed medicinal products derived from cannabis.
  • "I am thrilled to join the Curio Scientific Advisory Board to provide insight into a field I love.

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease

Retrieved on: 
Wednesday, September 27, 2023

"We are excited to expand our partnership with Roche, a global leader in developing and delivering innovative treatments to patients," said Brett P. Monia, Ph.D., Ionis' chief executive officer.

Key Points: 
  • "We are excited to expand our partnership with Roche, a global leader in developing and delivering innovative treatments to patients," said Brett P. Monia, Ph.D., Ionis' chief executive officer.
  • "With this new collaboration, we are joining forces to accelerate the discovery and development of novel therapies for people living with Alzheimer's disease and Huntington's disease globally.
  • Collaborating on these two programs enables Ionis to advance our wholly owned programs, including those in neurology, aligned with our strategic priorities."
  • IONIS-FB-LRx is currently in a Phase 2 study for GA, led by Ionis, and a Phase 3 study for IgAN led by Roche.

NTT and NCNP to Develop Brain Bio-Digital Twin Technology

Retrieved on: 
Thursday, September 14, 2023

NTT Corporation (NTT) and the National Center for Neurology and Psychiatry (NCNP) have entered into a partnership agreement to develop “Brain Bio-Digital Twin” technology.

Key Points: 
  • NTT Corporation (NTT) and the National Center for Neurology and Psychiatry (NCNP) have entered into a partnership agreement to develop “Brain Bio-Digital Twin” technology.
  • NTT and NCNP will initially focus on practical applications of this technology that eliminate the need for invasive and costly testing of various brain diseases.
  • The Brain Bio-Digital Twin incorporates various types of body data obtained through medical examinations into a computer as digital data and enables the creation of detailed maps and biological models through digital twin computing technology.
  • The practical application of the Brain Bio-Digital Twin will enable the "twin" to be used for testing, rather than the patient's own brain and nerves.

Cutaneous Lupus Erythematosus Market Insight & Forecast Reveals USD 1.2 Billion Growth Potential by 2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023

The "Cutaneous Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cutaneous Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the Cutaneous Lupus Erythematosus market in the 7MM and China was approximately USD 580 million, expected to reach USD 1.2 billion by 2032.
  • Notably, Biogen's litifilimab and Bristol Myers Squibb's deucravacitinib will lead the Cutaneous Lupus Erythematosus market in the forecast period.
  • In 2022, the total market size of Cutaneous lupus erythematosus in the 7MM and China was ~USD 580 million, expected to reach ~USD 1,260 million by 2032.

RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy

Retrieved on: 
Friday, July 28, 2023

PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy.

Key Points: 
  • PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring and Integrated Physician Alert System For Ocular Anatomy.
  • The current model of eye care, in which patients schedule in-person visits with eye specialists suffers from many drawbacks.
  • Ocular screening is important because, when a patient has diabetes, the earliest observable change to the body is in the eyes.
  • Katzman continued, "In light of the severe shortage of healthcare professionals, remote diagnostic technology is essential for efficient patient management.